Details der Publikation - A multi-centre, adaptive, randomized, double-blind, placebo-controlled comparative clinical study of the safety and efficacy of 12 mg Polyoxidonium®, lyophilizate solution for injections (NPO Petrovax Pharm LLC, Russia) in patients with coronavirus disease (COVID-19).

A multi-centre, adaptive, randomized, double-blind, placebo-controlled comparative clinical study of the safety and efficacy of 12 mg Polyoxidonium®, lyophilizate solution for injections (NPO Petrovax Pharm LLC, Russia) in patients with coronavirus disease (COVID-19). : A multi-centre, adaptive, randomized, double-blind, placebo-controlled comparative clinical trial of the safety and efficacy of 12 mg Polyoxidonium®, lyophilizate solution for injections (NPO Petrovax Pharm LLC, Russia), in patients with coronavirus disease (COVID-19)

Medienart:	Klinische Studie

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	WHO International Clinical Trials Registry Platform - (2021) vom: 07. Juni Zur Gesamtaufnahme - year:2021

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: MedDRA version: 21.1Level: PTClassification code 10035737Term: Pneumonia viralSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02] Phase: Phase 2 Recruitment Status: Not yet recruiting Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 15-06-2020, Last updated: 2022-11-24

ICTRP ID:	EUCTR2020-001782-37-SK P?-COV-III-20

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG006141765

Internformat


LEADER	01000caa a22002652 4500
001	CTG006141765
003	DE-627
005	20230425172906.0
007	cr uuu---uuuuu
008	210507s2021 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)CTG006141765
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2020-001782-37-SK
035			\|a (UBBS_Klinische_Studien_WHO)P?-COV-III-20
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a A multi-centre, adaptive, randomized, double-blind, placebo-controlled comparative clinical study of the safety and efficacy of 12 mg Polyoxidonium®, lyophilizate solution for injections (NPO Petrovax Pharm LLC, Russia) in patients with coronavirus disease (COVID-19). \|b A multi-centre, adaptive, randomized, double-blind, placebo-controlled comparative clinical trial of the safety and efficacy of 12 mg Polyoxidonium®, lyophilizate solution for injections (NPO Petrovax Pharm LLC, Russia), in patients with coronavirus disease (COVID-19)
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 15-06-2020, Last updated: 2022-11-24
650		4	\|a Medical Condition: MedDRA version: 21.1Level: PTClassification code 10035737Term: Pneumonia viralSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 2
650		4	\|a Recruitment Status: Not yet recruiting
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2021) vom: 07. Juni
773	1	8	\|g year:2021 \|g day:07 \|g month:06
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001782-37 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2021 \|b 07 \|c 06

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände